Opioid agonist treatment during SARS-CoV2 & extended lockdown: Adaptations & challenges in the Indian context

Asian J Psychiatr. 2020 Oct:53:102377. doi: 10.1016/j.ajp.2020.102377. Epub 2020 Aug 27.

Authors

Abhishek Ghosh¹, Shubhmohan Singh², Anirban Dutta³

Affiliations

¹ Drug De-addiction & Treatment Centre & Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India. Electronic address: ghoshabhishek12@gmail.com.
² Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India. Electronic address: shubhmohan@gmail.com.
³ University at Buffalo, Buffalo, NY, 14260, USA. Electronic address: anirband@buffalo.edu.

No abstract available

Publication types

Letter

MeSH terms

Analgesics, Opioid*
COVID-19*
Communicable Disease Control
Humans
RNA, Viral
SARS-CoV-2

Substances

Analgesics, Opioid
RNA, Viral